Breast cancer (BC) is the most common cancer and the second leading cause of cancer death in women. It is a highly variable ...

Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that PharosAI, a research consortium uniting four leading UK institutions, will use the 10x Genomics Xenium ...

As cancer survival continues to improve globally, attention is increasingly shifting toward survivorship outcomes that extend ...

Collaborative Nature Communications study with The University of Queensland, Yale School of Medicine, and Nucleai examines how tumor cell positioning and glucose use predict which NSCLC patients ...

Metastasis-directed therapy (MDT) delivered via stereotactic body radiotherapy has gained substantial attention over the past decade. Landmark trials such as STOMP1 and ORIOLE2 fundamentally shifted ...

Over recent decades, advances in cancer treatment have yielded substantial improvements in patient outcomes, driving up survival, and even rendering some cancers curable. These advances have been ...

Computational pathology is becoming increasingly important in helping deliver precision medicine to a wider range of patients. Experts at the 37th European Congress of Pathology in Vienna discussed ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare diseaseALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic ...

Detailed price information for Acrivon Therapeutics Inc (ACRV-Q) from The Globe and Mail including charting and trades.

Detailed price information for Acrivon Therapeutics Inc (ACRV-Q) from The Globe and Mail including charting and trades.

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER, BC, Jan. /CNW/ — Equity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering ...